Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00205322
Status:
COMPLETED
Last Update Posted:
2019-11-19
First Post:
2005-09-13
Brief Title:
Oxaliplatin 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
Sponsor:
University of Wisconsin Madison
Organization:
University of Wisconsin Madison
Study Overview
Official Title:
A Phase II Study of Oxaliplatin 5-fluorouracil and Leucovorin in Combination With Oral Capecitabine in Patients With Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The combination of oxaliplatin 5-FU leucovorin and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens Additionally the use of an oral rather than an infusional 5-fu regimen represents a clear advantage in terms of both patient convenience and lack of associated catheter-related complications
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SMPHMEDICINEH | OTHER | UW Madison | None |
| M-2003-0544 | OTHER | None | None |
| A534260 | OTHER | None | None |